Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Expression of TEL-JAK2 in primary human hematopoietic cells drives erythropoietin-independent erythropoiesis and induces myelofibrosis in vivo

2 Nov 2006

Abstract excerpt

Activation of JAK2 by chromosomal translocation or point mutation is a recurrent event in hematopoietic malignancies, including acute leukemias and myeloproliferative disorders. Although the effects of activated JAK2 signaling have been examined in cell lines and murine models, the functional consequences of deregulated JAK2 in the context of human hematopoietic cells are currently unknown. Here we report that...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytokine Signaling Pathways and Interactions
Share to Kruppel-like factors research
Share to Myeloproliferative Neoplasms: Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 17077140
DOI: 10.1073/pnas.0604902103

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Expression of TEL-JAK2 in primary human hematopoietic cells drives erythropoietin-independent erythropoiesis and induces myelofibrosis in vivoPMID 17077140Read ↗

JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F–positive essential thrombocythemiaSemantic proximity Read ↗

Transformation of hematopoietic cell lines to growth‐factor independence and induction of a fatal myelo‐ and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genesSemantic proximity Read ↗

Impact of isolated germline JAK2V617I mutation on human hematopoiesisSemantic proximity Read ↗

A unique activating mutation in JAK2 (V617F) is at the origin of polycythemia vera and allows a new classification of myeloproliferative diseases.Semantic proximity Read ↗

Genome editing to model and reverse a prevalent mutation associated with myeloproliferative neoplasmsSemantic proximity Read ↗

JAKing up hematopoietic proliferation.Semantic proximity Read ↗

Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera–like diseaseSemantic proximity Read ↗

The JAK-STAT pathway and hematopoietic stem cells from the JAK2 V617F perspectiveSemantic proximity Read ↗

Homologous recombination of wild-type JAK2, a novel early step in the development of myeloproliferative neoplasm.Semantic proximity Read ↗

Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation.Semantic proximity Read ↗

JAK2 V617F stimulates proliferation of erythropoietin-dependent erythroid progenitors and delays their differentiation by activating Stat1 and other nonerythroid signaling pathways.Semantic proximity Read ↗

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.